CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Moonwalk reloads with $70M and new RNAi prospects for obesity

Trial StartPositive
AI Analysis

Summary

Moonwalk secured $70M in funding and licensed RNAi technology from a Chinese drugmaker to develop its first obesity drug, with plans to enter clinical testing by end of 2027.

Importance:6/10
Sentiment:
0.60
RNAiobesitylicensingfundingclinical_development
Related Companies

Read the original article

Published by BioPharma Dive on September 8, 2026 3:52 PM

Read Original